In a clinical trial supported by Medtronic (Minneapolis), deep brain stimulation (DBS) significantly reduced seizure frequency among patients with medically refractory epilepsy with partial-onset seizures, a form of the neurological condition that does not respond well to antiepileptic drugs. The results from the study showed that stimulating the left and right anterior nucleus of the thalamus the brain's central message and relay station with Medtronic's DBS therapy for epilepsy in conjunction with epilepsy medications produced a statistically significant median percentage reduction in seizures compared to a no stimulation control group at the end of the blinded phase of the study.

• Nomir Medical Technologies (Waltham, Massachusetts) reported the presentation of positive in vivo human data for its Noveon direct optical energy device for treating methicillin-resistant Staphylococcus aureus (MRSA) colonization in the nose. The study demonstrated that light-based treatment with the Noveon resulted in reversal of microbial resistance to generic topical 2% erythromycin paste. The study confirmed two years of in vitro experimentation that indicate the device's method of action is due to a unique photo-inactivation effect. This method resulted in the eradication of erythromycin-resistant MRSA and erythromycin-resistant, methicillin-sensitive Staphylococcus aureus (MSSA) in the nose.